Strength Seen in Apellis Pharmaceuticals, Inc. (APLS): Can Its 16.3% Jump Turn into More Strength?

Zacks2023-04-04

Apellis Pharmaceuticals, Inc. (APLS) shares ended the last trading session 16.3% higher at $76.68. The jump came on an impressive volume with a higher-than-average number of shares changing hands in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2324871222?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/GaLI6UTOYfr9yVPRx4VoRg--~B/aD01OTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/57ec460cb6b81f1335dcfb164b86740c","is_english":true,"pubTime":"2023-04-04 16:02","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2324871222","market":"us","top_or_hot":-1,"title":"Strength Seen in Apellis Pharmaceuticals, Inc. (APLS): Can Its 16.3% Jump Turn into More Strength?","media":"Zacks","content":"<div>\n<p>Apellis Pharmaceuticals, Inc. (APLS) shares ended the last trading session 16.3% higher at $76.68. The jump came on an impressive volume with a higher-than-average number of shares changing hands in ...</p>\n\n<a href=\"https://finance.yahoo.com/news/strength-seen-apellis-pharmaceuticals-inc-080208476.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Strength Seen in Apellis Pharmaceuticals, Inc. (APLS): Can Its 16.3% Jump Turn into More Strength?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStrength Seen in Apellis Pharmaceuticals, Inc. (APLS): Can Its 16.3% Jump Turn into More Strength?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-04-04 16:02 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/strength-seen-apellis-pharmaceuticals-inc-080208476.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apellis Pharmaceuticals, Inc. (APLS) shares ended the last trading session 16.3% higher at $76.68. The jump came on an impressive volume with a higher-than-average number of shares changing hands in ...</p>\n\n<a href=\"https://finance.yahoo.com/news/strength-seen-apellis-pharmaceuticals-inc-080208476.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BOLT","symbol_name":"Bolt Biotherapeutics, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/strength-seen-apellis-pharmaceuticals-inc-080208476.html","article_id":"2324871222","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/GaLI6UTOYfr9yVPRx4VoRg--~B/aD01OTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/57ec460cb6b81f1335dcfb164b86740c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2324871222","pubTimestamp":1680595328,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Apellis Pharmaceuticals, Inc. (APLS) shares ended the last trading session 16.3% higher at $76.68. T","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BOLT":"Bolt Biotherapeutics, Inc.","CRCT":"Cricut, Inc.","BK4139":"生物科技","BK4505":"高瓴资本持仓","BK4539":"次新股","TERN":"Terns Pharmaceuticals, Inc.","BK4007":"制药","APLS":"Apellis Pharmaceuticals Inc.","BK4191":"家用电器","PRVB":"Provention Bio, Inc"},"translate_title":"Apellis Pharmaceuticals，Inc.（APLS）的实力：其16.3%的涨幅能转化为更大的实力吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLS":1,"BOLT":1,"CRCT":1,"TERN":1,"PRVB":0.9},"content_text":"Apellis Pharmaceuticals, Inc. (APLS) shares ended the last trading session 16.3% higher at $76.68. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1.5% gain over the past four weeks.\nThe sudden soaring of stock prices is likely due to a Bloomberg article which claims, Apellis is considering a possible buyout by larger pharma companies. Per the article, the company has been holding discussions with its advisors to evaluate its options for a possible takeover. The article further states that Apellis might also be looking for partnerships or licensing agreements for some of its ophthalmology products. However, in the absence of a statement from Apellis, there is no certainty of any transaction.\nThis company is expected to post quarterly loss of $1.69 per share in its upcoming report, which represents a year-over-year change of -19%. Revenues are expected to be $26.09 million, up 81.4% from the year-ago quarter.\nEarnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.\nFor Apellis Pharmaceuticals, Inc., the consensus EPS estimate for the quarter has been revised marginally lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on APLS going forward to see if this recent jump can turn into more strength down the road.\nThe stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>\nApellis Pharmaceuticals, Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Provention Bio, Inc. (PRVB), closed the last trading session 0.8% higher at $24.30. Over the past month, PRVB has returned 194.6%.\nProvention Bio, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.31. Compared to the company's year-ago EPS, this represents a change of +11.4%. Provention Bio, Inc. currently boasts a Zacks Rank of #3 (Hold).\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nApellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report\nProvention Bio, Inc. (PRVB) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2324871222"}